Skip to Main Content

After Pfizer deferred hefty price hikes under pressure from President Trump, a lawmaker is asking the company and the administration to explain the details of any agreements that may have been reached as part of the sudden about-face.

Specifically, Sen. Ron Wyden (D-Ore.) wants to know if Pfizer (PFE) received any preferential treatment; what, if any, steps must be taken by the government for Pfizer to further delay price hikes; explain how the administration avoided interfering with any contracts Pfizer has with Medicare Part D plans; and whether the administration plans to approach other drug makers, among other things.


“Secret, sweetheart arrangements with pharmaceutical companies are exactly why America’s drug pricing system is broken,” Wyden said in a statement in which he also released copies of letters (see here and here) sent to Pfizer chief executive Ian Read and Health and Human Services Secretary Alex Azar.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.